74 results about "Coxsackievirus a16" patented technology

The invention discloses a univalent and bivalent inactivated vaccine for preventing Enterovirus 71 (EV71) and Coxsackie virus A16 (Cox.A16) of hand-foot-and-mouth disease, and a preparation method thereof. The preparation method comprises the following steps: screening vaccine strains for the hand-foot-and-mouth disease; establishing and verifying a vaccine strain third-stage seed lot library; culturing cells; inoculating and propagating virus; collecting virus suspension; inactivating the virus; ultra-filtering, concentrating and purifying the virus suspension to obtain vaccine stock solution; and finally preparing the univalent and bivalent inactivated vaccine. The univalent and bivalent inactivated vaccine has good application prospect for preventing the hand-foot-and-mouth disease.

The invention discloses a univalent and bivalent gene engineered subunit vaccine for preventing Enterovirus 71 (EV71) and Coxsackie virus A16 (Cox.A16) of hand-foot-and-mouth disease, and a preparation method thereof. The preparation method comprises the following steps: respectively obtaining recombinant baculovirus Bac-EV71-P1-3CD and Bac-Cox.A16-P1-3CD by gene engineering means, respectively efficiently coexpressing similar SeQ ID No.1 EV71 P1 and Se Q ID No.2 Cox.A16 P1 and 3CD proteins in insect cells, and respectively self-assembling into EV71 VLP and Cox.A16 VLP; establishing and verifying a vaccine strain third-stage seed lot library; culturing cells; inoculating and propagating virus; lysing the cells, ultra-filtering and purifying virus suspension; and further preparing the univalent and bivalent vaccine. The vaccine has good application prospect for preventing the hand-foot-and-mouth disease.

The invention provides a three-color fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) combined detection method of enterovirus 71, Coxsackie virus A16 and other subtypes of enterovirus as well as a kit thereof. The method can rapidly and accurately detect the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of enterovirus in a sample. The method comprises the following steps of: (1) acquiring and conveying a sample of an infected patient or a suspected patient; (2) preprocessing the sample and extracting RNA; (3) detecting the sample by adopting a one-step PCR-three-color fluorescent probe in-vitro amplification method; and (4) analyzing the corresponding sample according to the fluorescence intensity of each amplification reaction after the amplification reaction is finished, thereby judging the existence of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus in the acquired sample and being capable of carrying out accurate quantitation (a figure 3) on the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus. The invention realizes the aim of carrying out rapid and accurate combined detection of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus.

The invention relates to a coxsackie virus A16 type virus-like particle vaccine. The inventor fortuitously finds that proteins which have better spatial configurations and are suitably cut can be obtained by expressing P1 protein of CVA16 and 3CD protein of CVA16 by infecting insect cells with rhabdovirus. The proteins can be automatically assembled into a virus-like particle which has high immunogenicity.

The invention discloses a preparation method for a recombinant coxsackie virus A16 like particle, which comprises the following steps: (1) cloning a P1 gene and a 3CD gene of a coxsackie virus A16 to a target plasmid to obtain a recombinant expression vector; (2) transforming a target yeast cell by using the recombinant expression vector obtained in the step (1) to obtain a recombinant yeast cellfor expressing the P1 gene and the 3CD gene; and (3) cracking the recombinant yeast cell obtained in the step (2), and separating to obtain the recombinant coxsackie virus A16 like particle. The recombinant coxsackie virus A16 like particle can be prepared in a yeast expression system by the method provided by the invention. Compared with a wild-type P1 gene and a wild-type 3CD gene, the yield ofthe coxsackie virus A16 like particle in the yeast expression system is greatly increased through the optimization of codons of the P1 gene and the 3CD gene, and the recombinant coxsackie virus A16 like particle can be further used for producing candidate preventive vaccines and pharmaceutical compositions for infant hand-foot-and-mouth diseases.

The invention provides a Coxsackie virus A16 virus strain, uses of the strain, a vaccine and a preparation method of the vaccine. The preservation number of the Coxsackie virus A16 virus strain is CGMCC No.6954. The CA16 virus strain has strong virulence, can be used for evaluating the CA16 vaccine, and can also be used for researching the CA16 virus infection mechanism. A method for establishing a Coxsackie virus A16 infected animal model provided by the invention can provide a stable animal model, and provides a foundation for the development of the Coxsackie virus A16 vaccine, the screening of antiviral drugs and the researches of the CA16 virus infection mechanism. The vaccine prepared by using the CA16 virus has effective immune activity.

The invention provides a coxsackie virus A16-type virus strain. The collection number of the coxsackie virus A16-type virus strain is CGMCC No.5372, wherein CGMCC refers to China General Microbiological Culture Collection Center. The virus is a 20-face stereoscopic symmetrical sphere under observation through an electron microscope, and the diameter of the virus is 23-30nm. VP1 conserved region sequence analysis and mass spectrum analysis are respectively performed on the virus strain, and a result shows a CA16 virus. The CA16 virus can be efficiently proliferated in Vero cells (African green monkey kidney cells), and the virus titer can reach 6.61g CCID50/ml. Moreover, the virus strain has no external pollution, better immunogenicity and a good effect.

The present invention relates to viral particles as immunogens against enterovirus infection and a method of producing the same. Specifically, the present invention features that human embryo kidney 293 (HEK 293) cells are used to produce viral particles of Enterovirus A, particularly Coxsackievirus A6 (CVA6) particles or Coxsackievirus A10 (CVA10) particles or both and optionally additional viral particles of other Enterovirus A e.g. Coxsackievirus A16 (CVA16) and/or Enterovirus A71 (EV71). The yield of the viral particles in HEK 293 cells is unexpectedly high and effective to induce an immune response against enterovirus infection, especially CVA6 and CVA10. The present invention also relates to an immunogenic composition against enterovirus infection for human use comprising the viral particles as described herein and a method of preventing enterovirus infection or a disease as caused, particularly Hand-Foot-Mouth diseases (HFMD), by administering the immunogenic composition to a subject in need thereof.

The invention provides an A16 type strain of Coxsackie virus, which has the preservation number of CGMCC No. 5373. When observed with an electronic microscope, the virus is in the shape of an icosahedral three-dimensional symmetrical sphere with the diameter of 23-30nm. VP1 conserved region sequence analysis and mass spectrum analysis are respectively conducted for the strain, and the results indicate that the strain is CA 16 virus which can be efficiently proliferated in Vero cells, and the virus titer can reach 7.01g CCID50/ml, and furthermore, the strain is free of extraneous contamination, and has good immunogenicity and excellent effects.

The present invention provides a method for purifying recombinant coxsackievirus A16 (CA16) virus-like particles, an application thereof in an vaccine, and the vaccine. The method comprises carrying out high density fermentation culture of recombinantly expressed engineering bacteria and methanol-induced expression of CA16 viroid granulin, carrying out centrifugation for collecting thalli, performing high-pressure homogenization and breaking, and purifying the supernatant by ultrafiltration, ion exchange chromatography, hydroxyapatite chromatography and molecular sieve chromatography and the like. The CA16 viroid particle vaccine provided by the invention has good immunogenicity, safety, immunological characteristics and biological activity. The process is simple, and the purification is performed by chromatographic methods. The purification method is more conducive to linear amplification compared with density gradient centrifugation, and can be used in large-scale preparation and purification, and a high-purity (more than 99%) virus-like particle (VLP) stock solution can be obtained and can be used to prepare a vaccine for preventing CA16 infection, and has good economic value and application prospects.

The embodiment of the invention discloses a nucleic acid fluorescence PCR detection kit for a universal enterovirus, a coxsackievirus A16 and an enterovirus 71. The nucleic acid fluorescence PCR detection kit comprises an RNA extracting solution, an RNA eluant, internal standards, a PCR reaction solution, an EV/CA16/EV71 enzyme mixed solution, EV/CA16/EV71 positive reference substances and EV/CA16/EV71 negative reference substances. According to the kit, the universal enterovirus, the coxsackievirus A16 and the enterovirus 71 can be simultaneously detected in a same sample, but other pathogen RNA cannot be detected, the detection sensitivity can reach 400 copie/ml, the detection range is 4.0 E+02-4.0E+08 copies/ml, and a reliable experimental evidence is supplied to early diagnosis on infection of the universal enterovirus, the coxsackievirus A16 and the enterovirus 71.

The invention discloses a kit for detecting coxsackie virus A16-type nucleic acid and a detection method thereof. The kit comprises PCR reaction enzyme, PCR reaction liquid, a negative quality control product and a positive quality control product, wherein the PCR reaction enzyme contains a hot start Taq enzyme, a MLV reverse transcriptase and a RNA enzyme inhibitor; the PCR reaction liquid contains DEPC treating water, dNTPs, 10*PCR Buffer, a coxsackie virus A16-type forward primer, a coxsackie virus A16-type reverse primer and a coxsackie virus A16-type probe, the sequence of the coxsackie virus A16-type forward primer is 5'-CGCTGCCGATACTGAAGCACCG-3', the sequence of the coxsackie virus A16-type reverse primer is 5'-CTGTCTCCGCGGCTTGTAG-3', the sequence of the coxsackie virus A16-type probe is 5'-ACAGATTAGGCACTGGTGTTGTACCGTA-3'; the negative quality control product is the DEPC treating water; and the positive quality control product is the prepared transcription in vitro RNA standard product. The method for fast detecting the sequence of the coxsackie virus A16-type nucleic acid by using a real-time fluorescence quantitative PCR technology has the advantages of specificity, sensitiveness, high speed as well as simple and convenient operation.

The invention belongs to biological field, and relates to a reagent kit for detecting main pathogen Coxsackievirus A16 (Cox A16) and enterovirus 71 of hand-foot-mouth disease, construction method and uses thereof. The reagent kit comprises reaction solutions for detecting four primers of Coxsackievirus A16 and four primers of enterovirus 71.As detected, the reagent kit has a good performance of specificity, sensitivity, rapid amplification, high efficiency and simple identification. The detection system of the invention can detect Coxsackievirus A16 and enterovirus 71 quickly, conveniently, high-effectively, high-specifically and highly-sensitive under temperature of 64 DEG C without need of complicated instruments, which can preferably satisfy clinical detection for hand-foot-mouth disease and be easily popularized in large scope.

The invention relates to the field of biological assay technical application, and in particular relates to a coxsackie virus A16 type RT-LAMP (reverse transcription-loop-mediated isothermal amplification) nucleic acid assay kit. The kit comprises RT-LAMP reaction solutions containing four RT-LAMP primers, as well as 10000X SYBR Green I dye. The kit has the characteristics of good specificity, high sensitivity, simple operation method, quick assay, easily judged result, low cost and the like, can well fulfill the current urging requirement for field assay of hand-foot-and-mouth disease, can beused for field quick assay of disease prevention and control institutions, hospitals and kindergartens, is easy for large-scale popularization and application in grass-roots places, and has wide market prospect and great economical and social benefit.

The invention relates to a primer for coxsackie virus A16 nucleic acid detection, probe and kit, wherein the nucleotide sequence of the primer is that: forward primer 5'-GAACCATCACTCCACACAGGAG-3'; backward primer 5'-GTACCCGTGGTGGGCATTG-3' and the nucleotide sequence of the probe is 5'-CAGCCATTGGGAATTTCTTTAGCCGTG-3'. The invention also provides a method for detecting coxsackie virus A16 nucleic acid. Sample RNA is used as template and the above primer and probe are subjected to real-time fluorescence RT-PCR amplification and the result is predicated based on the amplification curve after each circulation. The primer specificity is good, the detection method is quick and simple, the accuracy and the sensitivity is high and the invention provides scientific reference for etiologic diagnosis and differential diagnosis of hand-foot-mouth disease and relative diseases.

The invention relates to new application of luteolin, in particular to application of luteolin in preparing medicine for preventing and treating hand-foot-mouth diseases, particularly, medicine used for resisting enterovirus 71 and/or coxsackievirus A16.

The invention relates to the application of Shuqing granules in preparing medicine for resisting hand-foot-and-mouth disease pathogens, and belongs to traditional Chinese medicine field. The invention comprises the application of the Shuqing granules in preparing medicine for resisting hand-foot-and-mouth disease pathogens, the application of the Shuqing granules in preparing medicine for resisting enterovirus 71 and the application of the Shuqing granules in preparing medicine for resisting coxsackievirus A16. The invention proves that Shuqing granules has an effect of treating the hand-foot-and-mouth disease, and provides the scientific basis for promoting traditional antiviral Chinese medicine and effectively preventing and treating the hand-foot-and-mouth disease.

The invention relates to preparation and application of an anti-Coxsackie virus A16 (CA16) monoclonal antibody. The invention reveals a mouse source anti-CA16 monoclonal antibody, which has good binding specificity, can be used for sensitive detection of Coxsackie A16 virus, and has strong anti-virus infection capacity.

The invention provides a detection test strip for a coxsackie virus A16 type (CA16) IgM (Immune Globulin M) antibody. According to the detection test strip, a nitrocellulose membrane (NC membrane) is coated by a CA16 gene antigen (VP1) and an anti-mouse IgG; and by combining a tihuman IgM monoclonal antibody labeled by colloidal gold, a CA16 specificity IgM antibody in an infected human speciment is detected by applying a membrane chromatography capture method. The test strip for detection, which is disclosed by the invention, has the advantages of simpleness, convenience, quickness and fastness in operation, no need of special instrument or special training, distinct and easily-distinguished result and easiness for popularization; and the detection test strip is suitable for field detection and early-stage diagnosis and assisting function for CA16 infected diagnosis.

The invention relates to a conservative neutralizing epitope polypeptide of Coxsackievirus A16 and application thereof. Specifically, the invention provides the neutralizing epitope polypeptide of Coxsackievirus A16, and also provides a binding molecule able to specifically bind with the neutralizing epitope polypeptide, antiserum containing the binding molecule, a kit for detecting the Coxsackievirus A16, a detection method and a composition inhibiting the Coxsackievirus A16. The invention also provides application of the neutralizing epitope polypeptide, the binding molecule and the antiserum in preparation of drugs for preventing and treating hand, foot and mouth disease and diagnostic agents for diagnosing hand, foot and mouth disease. According to the invention, 6 linear neutralizing epitopes on CA16VP1 are identified for the first time, the comparison result of different genotype CA16 sequences shows that the epitopes are very conservative, and the serum brought about by immunizing mice with the neutralizing epitope polypeptide can neutralize homologous and heterogenous CA16 strains. The results have important guiding significance on development of Coxsackievirus A16 vaccines and diagnostic kits.

The embodiment of the invention discloses a nucleic acid fluorescent PCR detection kit for coxsacki evirus A16 and human enter ovirus 71. The nucleic acid fluorescent PCR detection kit comprises the following components: RNA extract solution, RNA eluant, internal standard substance, PCR reaction liquid, CA16/EV 71 enzyme mixed liquid, CA16/EV 71 positive control substance and CA16/EV 71 negative control substance. According to the nucleic acid fluorescent PCR detection kit, two kinds of enteroviruses including the coxsacki evirus A16 and human enter ovirus 71 are simultaneously detected in one sample, other pathogen RNAs can not be detected, and RNAs are extracted by a paramagnetic particle method, so that the detection sensitivity, accuracy and stability are improved, the detection sensitivity achieves 400 copie/ml, the detection range is (4.0E+02)-(4.0E+08) copies/ml, and reliabile experimental evidences are provided for early diagnosis of the infection of the coxsacki evirus A16 and the human enter ovirus 71.

The invention belongs to the fields of molecular biology, virology and immunology, and relates to a nucleic acid construct and a method for preparing coxsackievirus A16 virus-like particles. The invention also relates to recombinant vectors and recombinant host cells comprising the nucleic acid construct. The invention further relates to a method and a purification method for co-expressing coxsackievirus A16 type capsid proteins VP1, VP2, VP3 and VP4 in series, a method for preparing the coxsackievirus A16 type virus-like particles, and the like. Further, the invention relates to the coxsackievirus A16 type virus-like particles and a pharmaceutical composition containing the same, such as a vaccine. By adopting the nucleic acid construct and the method, soluble co-expression of the capsidproteins of a human hand-foot-and-mouth disease virus (coxsackievirus A16 type) in escherichia coli is realized, and the expression quantity is relatively high; finally obtained interest proteins account for about 10% of the total soluble proteins in bacteria; and the coxsackievirus A16 virus-like particles comprising the interest proteins are highly similar to native coxsackievirus A16 conformation.

The invention relates to a preparation method of a hand-foot-and-mouth disease etiology colloidal gold diagnosis detection test paper box, and the method is capable of effectively solving the problems of low detection sensitiveness, low accuracy, high detection leakage possibility and difficult specimen collection in the prior art. The method comprises the following steps of: firstly adhering a reaction film to the center of a backlining; spraying a detection line and a control line on the reaction film; pressing a water absorption cushion to one side, which is adjacent to the tail end of the backlining, of the reaction film, pressing a colloidal gold cushion to the other side of the reaction film, pressing a sample cushion to the other side of the colloidal gold cushion; fixing the sample cushion, the colloidal gold cushion, the reaction film and the water absorption cushion to the backlining; cutting into 4mm-width strips along the cross section direction of the backlining by use of a slitter; assembling testpaper into a testpaper shell, and forming a sample hole and a detection result region on the test paper shell. The high-sensitivity hand-foot-and-mouth disease etiology rapid detection test paper prepared by anti-enterovirus 71 type specific monoclonal antibodies and anti-coxsackievirus A16 type specific monoclonal antibodies is good in detection sensitivity, high in accuracy and low in detection leakage possibility.